|
- News | Amgen
Clinical Trial Diversity and Representation Information for Healthcare Professionals Clinical Trial Transparency, Data Sharing and Disclosure Practices Clinical Out-of-Hours Support program
- Amgen says Imdelltra extended survival; Parker Institute adds new . . .
Today, a brief rundown of news involving Amgen and the Parker Institute, as well as updates from J J, Alzheon and Amylyx Pharmaceuticals that you may have missed New data visualizations published by BioPharma Dive capture the year-to-date funding trends for 2025, which so far include a pullback in
- Investors | Amgen Inc.
ALL EVENTS Recent News NEWS RELEASE06 30 2025 AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER NEWS RELEASE06 23 2025 RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC
- Bristol pulls ahead of Amgen | ApexOnco - Clinical Trials news and analysis
The company will start a phase 2 3 trial of its Mirati-originated PRMT5 inhibitor in autumn
- With biosimilar sales up 16%, Amgen expects larger boost in 2025
With recent launches of biosimilar versions of Eylea and Stelara, Amgen projects biosimilar sales to reach $4 billion by the end of the decade
- Amgen | A Worldwide Pioneer in Biotechnology
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics
- Inspired by Nature: How Amgen Designs the Future of Medicine
Nature has long held the blueprint for the next generation of medicines Amgen is inspired by nature's building blocks – proteins, peptides and RNA – to design and invent innovative therapies that mirror, enhance or redirect mechanisms that occur in nature
- Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut . . .
Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Travere Therapeutics, Allogene and Kyverna Therapeutics that you may have missed Sino's acquisition of LaNova Medicines is the first large buyout of a China-based drugmaker tracked by BioPharma Dive since BioNTech
|
|
|